Ignite Creation Date:
2025-12-24 @ 5:53 PM
Ignite Modification Date:
2026-02-05 @ 8:55 PM
Study NCT ID:
NCT00603668
Status:
COMPLETED
Last Update Posted:
2021-08-16
First Post:
2008-01-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
Sponsor:
Gilead Sciences
Organization: